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Acetaminophen Protects Against Iron-Induced
Cardiac Damage in Gerbils

Ernest M. Walker, Jr.,1,2 Christopher P. Epling,2 Cordel Parris,2 Silvestre Cansino,2 Protip Ghosh,3
Devashish H. Desai,4 Ryan G. Morrison,4 Gary L. Wright,4 Paulette Wehner,2 Elsa I. Mangiarua,4
Sandra M. Walker,5 and Eric R. Blough6
1 Pathology, 2 Cardiovascular Services, 3 Geology, 4 Physiology,,and 6 Biology Departments, Marshall
University; 5 Marshall Community & Technical College and St Mary’s Medical Center, Huntington,
WestVirginia
Abstract. There are few eﬀective agents that safely remove excess iron from iron-overloaded individuals.
Our goal was to evaluate the iron-removing eﬀectiveness of acetaminophen given ip or orally in the gerbil
iron-overload model. Male gerbils were divided into 5 groups: saline controls, iron-overloaded controls,
iron-overloaded treated with ip acetaminophen, iron-overloaded treated with oral acetaminophen, and
iron-overloaded treated with ip deferoxamine. Iron dextran was injected ip twice/wk for 8 wk. Acetaminophen
and deferoxamine treatments were given on Mondays, Wednesdays, and Fridays during the same 8 wk and
continued for 4 wk after completion of iron-overloading. Echocardiograms were performed after completion
of the iron-overloading and drug treatments. Liver and cardiac iron contents were determined by inductively
coupled plasma atomic emission spectrometry (ICP-AES). Iron-overloaded controls had 232-fold and 16fold increases in liver and cardiac iron content, respectively, compared to saline controls. In iron-overloaded
controls, echocardiography showed cardiac hypertrophy, right and left ventricular distension, signiﬁcant
reduction in left ventricular ejection fraction (-22%), and fractional shortening (-31%) during systole.
Treatments with acetaminophen (ip or oral) or deferoxamine (ip) were equally eﬀective in reducing cardiac
iron content and in preventing cardiac structural and functional changes. Both agents also signiﬁcantly
reduced excess hepatic iron content, although acetaminophen was less eﬀective than deferoxamine. The
results suggest that acetaminophen may be useful for treatment of iron-induced pathology.
Keywords: acetaminophen, deferoxamine, echocardiogram, iron-overload, gerbils, hemochromatosis
Introduction
It is estimated that >2 million persons in the United
States and up to 100 million persons worldwide
acquire some degree of iron-overload [1]. There are
2 major causes of iron-overload in humans. The
ﬁrst is transfusional iron-overload, resulting from
frequent blood transfusions in patients with thalassemia, sickle cell disease, or myelodysplastic syndrome. The second is hereditary hemochromatosis,
Address correspondence to Ernest M. Walker, Jr., M.D.,
Ph.D., Pathology Department, Marshall University Medical
School, 1542 Spring Valley Drive, Huntington, WV 25704,
USA; tel 304 696 72766; fax 304 696 6777; e-mail walkere@
marshall.ucla.edu.

an autosomal recessive disorder with a frequency of
about 10% in persons of European descent [2-4].
While only 0.5% of subjects are homozygous for
this trait, nearly 40 million people worldwide have
iron-overload due to hereditary hemochromatosis
and various types of hemosiderosis. In these cases,
tissue iron levels progressively increase with age
and may cause life-threatening complications.
These include advanced liver disease and cirrhosis,
diabetes mellitus likely due to accumulation of iron
in pancreatic islets with direct damage to beta cells,
and cardiotoxicity due to accumulation of iron in
myocytes and interstitial cells of the myocardium,
and within the ﬁbers of the conduction system.
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Cardiomyopathy from excess cardiac iron is
the major cause of death in thalassemia patients
[5,6]. Excess iron accumulation in the heart may
cause cardiac hypertrophy, dilatation, myocardial
ﬁber degeneration, and ﬁbrosis [7]. The survival of
patients with beta thalassemia and sickle cell
anemia is determined by the magnitude of cardiac
iron-loading [8]. Removal of excess iron is necessary
to improve morbidity and reduce mortality of
patients with thalassemia and sickle cell disease [7].
Cardiotoxic eﬀects may be severe, with cellular
degeneration and ﬁbrosis of the myocardium,
disturbances of cardiac rhythm, and eventual
death. However, even individuals with only mild
to moderate elevations of tissue iron appear to have
increased risk for diabetes mellitus, heart disease,
G-I cancers, and hematological malignancies [1].
Treatment with phlebotomy results in some
clinical improvement of subjects with elevations in
tissue iron burden and, if used as preventive therapy,
may ameliorate organ damage and result in normal
life expectancy [9]. However, this treatment requires
repeated removal of up to a liter of blood for periods
of a year or longer, followed by lifetime maintenance
phlebotomy. Chelation therapy with currently
approved chelating agents is a poor substitute for
phlebotomy and is used mainly in treating patients
with secondary hemochromatosis or hemosiderosis.
There are currently 3 iron chelators in clinical use
or in late-stage development; these are Desferal
(deferoxamine), deferiprone (L1), and Exjade
(deferasirox, ICL670) [6].
Desferal (deferoxamine). The major chelator
agent approved for iron removal in humans is
deferoxamine, which may be beneﬁcial as a cardioprotective agent through its ability to remove excess
iron and possibly to act as an antioxidant.
Deferoxamine has demonstrated eﬃcacy in
removing excess iron, preventing early death, and
improving survival rates in thalassemia patients
[6,10,11]. Deferoxamine must be administered by
iv, sc, or im routes and is ineﬀective when given
orally. It can be associated with side eﬀects such as
visual and auditory disturbances, urticaria, hypotension, poor patient tolerance, and low compliance
[6,7,8,12,13]. Deferoxamine is a hexadentate
chelator that combines with iron at a 1:1 ratio to
form a stable inert complex [14].

Deferiprone (L1). Deferiprone is approved as a
second-line therapy for patients unable to receive
deferoxamine or in whom deferoxamine is less
eﬀective [6]. Deferiprone is eﬀective orally, but has
a short half-life so that multiple daily oral doses are
required. It is associated with serious toxic side
eﬀects in some recipients, including increase of
serum transaminase activity, joint problems,
neutropenia, and agranulocytosis [6,8,14]. There is
a risk of paradoxical aggravation of iron toxicity by
deferiprone [14]. Liver iron levels and body burdens
of iron may not be as well controlled for long
periods (4-6 yr) with deferiprone vs deferoxamine
and may remain at levels above the threshold
associated with heart disease in 18% to 65% of
patients [8,15-20]. Beneﬁcial eﬀects of deferiprone
on heart disease are unclear and appear to be
improved when the agent is given in combination
with deferoxamine [8,21]. Three molecules of
deferiprone are required to bind one molecule of
iron [6,8]. The use of deferiprone may produce zinc
deﬁciency in some patients [6].
Exjade (deferasirox, ICL670, Novartis).
Deferasirox has recently been evaluated in phase
IIb/III studies and approved for clinical use. It has
a long half-life so that it can be used for once-daily
dosing [6,22,23]. Early clinical results suggest that
reasonable doses of deferasirox eﬀectively control
excess iron levels and that deferasirox has equivalent
eﬃcacy to deferoxamine [6]. Deferasirox also shows
high eﬃcacy and therapeutic safety in preclinical
animal studies [8,24,25]. Two molecules of
deferasirox bind one molecule of ferric iron [6].
There is a great clinical need for an orally active
iron-chelating drug for treating cases of ironoverload. Based on earlier work by our laboratory
[26], we tested the eﬀectiveness of acetaminophen,
given ip or orally, for the reduction of tissue iron
levels and prevention of cardiopathology in the
Mongolian golden gerbil iron-overload model.
Materials and Methods
Animals. Twelve-wk-old male pathogen-free Mongolian
golden gerbils (Hilltop Laboratories, Scottsdale, PA) were
housed on wood chip bedding in plastic cages in rooms kept
at 23 ± 2°C with a 12 hr light/dark cycle. Purina gerbil mix
and tap water were available ad libitum. All animal procedures
were approved by the Marshall University Institutional
Animal Care and Use Committee.
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Table 1. Disposition of gerbils in the 5 experimental groups.
Experimental group
Saline controls (SC) (n = 16)
Iron-overload controls (IO) (n = 16)
Iron-overload acetaminophen ip (IOAi) (n = 16)
Iron-overload acetaminophen po (IOAo) (n = 16)
Iron-overload deferoxamine ip (IODF) (n = 16)

Mortality
0
3
1
0
3

ECHO studies Used for histology
16
15
9
10
7

6
6
6
6
6

Analyzed for iron
10
10*
9
10
7

*Three iron-overloaded animals died during or after ECHO procedures and their hearts and livers were salvaged for determination
of iron content. There were no statistically signiﬁcant diﬀerences among the groups regarding mortality.
Treatments. Animals (average wt 60 g) were divided into 5
groups (16 gerbils/group). (SC)saline control gerbils received
ip injection of 1% saline (0.15 ml/kg) twice/wk for 8 wk. (IO)
iron-overloaded control animals were subjected to a similar
schedule of twice/wk ip injections of iron dextran (120 mg/
kg, ferric hydroxide dextran complex, Sigma Chemical Co.,
St. Louis, MO) dissolved in 1% saline. (IOAi) acetaminopheninjected animals received ip injections of iron dextran twice/
wk and acetaminophen (150 mg/kg or 1.0 mM/kg, 4acetaminophen, Sigma) 3 times/wk (Monday, Wednesday,
Friday). Acetaminophen was injected 4 hr after the iron
injection when both were given on the same days. The
acetaminophen treatment was continued 3 times/wk (M,W,F)
for 4 wk after the completion of iron-overloading. (IOAo)
these animals, which received oral acetaminophen, were given
ip iron dextran twice/weekly and acetaminophen (150 mg/kg
in saline) by gavage 3 times/wk (M,W,F) for the ﬁrst 9
treatments. Animal distress due to repeated gavages forced
additional oral acetaminophen to be given in drinking water
at an initial acetaminophen concentration of about 1.2 mg/
ml. Water intake was monitored and averaged 5 ml/gerbil/
day. Animals were periodically weighed and the acetaminophen
concentration adjusted as necessary to regulate the oral dosage
(approximately 100 mg/kg/day). Oral acetaminophen treatment was continued for 4 wk after completion of ironoverloading. (IODF) this group of gerbils received ip iron
dextran twice/wk and deferoxamine (IODF) 3 times/wk.
Deferoxamine in the form of the methanesulfonate salt (82
mg/kg or 0.125 mM/kg, Sigma) was administered about 4 hr
after the iron injection when both were given on the same
days. Deferoxamine treatment was continued 3 times/wk for
4 wk after the completion of iron-overloading, so that the
total period of treatment and observation was 12 wk. ECHO
studies were conducted on all gerbils 8 wk after completion of
treatment and the gerbils were killed at 20-21 wk into the
experiment for histopathologic studies and measurements of
cardiac and hepatic iron contents. The disposition of gerbils
in the 5 experimental groups is listed in Table 1.
ECHO studies. ECHO cardiac structural and functional
values have not previously been reported for gerbils. Groups
of control gerbils (n = 16) and iron-overloaded gerbils (n = 16
less one death, or n = 15) were studied to ensure the validity
and statistical power of the results. Nine of 16 iron-overloaded,
acetaminophen-injected (IOAi), 10 of 16 iron-overloaded,
acetaminophen orally administered, and 7 of 16 iron-

overloaded, deferoxamine injected animals were randomly
selected for ECHO studies. One IOAi gerbil died during
ECHO studies and 6 IOAi gerbils were used for non-ECHO
studies. Six IOAo gerbils were used for non-ECHO studies.
Three IODF gerbils died prior to, during, or just after ECHO
studies and 6 were used for non-ECHO studies.
Echocardiography is a noninvasive ultrasound procedure
in which harmless, high-frequency sound waves (frequency
>20,000 cycles/sec) are emitted from a piezoelectric crystal or
transducer, beamed in particular directions, and reﬂected
back (echo) by small structures in the mm and sub-mm range
[27]. These waves are beamed toward and penetrate the heart
and are reﬂected back to the transducer as a series of echoes,
which are ampliﬁed and displayed on a cathode ray tube [28].
Echocardiography is used to evaluate the position, size, and
movement of cardiac valves, heart wall structure and function,
and directional ﬂow of blood within cardiac chambers [29].
Echocardiographic measurements were done with a
Phillips Sonos 5500 echocardiogram using a S12 transducer
(frequency range 8-12 MHz). Animals were anesthetized with
ip injections of a 2:1 mixture of ketamine HCl (100 mg/ml)
and xylazine (20 mg/ml) (approximately 0.3 to 0.4 ml/100 g
gerbil wt). Gerbils were shaved in the chest area for adequate
sonic transference, an ultrasonic transmission gel was applied
to the chest area, and the animals were positioned on their left
sides or backs. Echocardiographic images were obtained
including two-dimensional, pulse wave Doppler and M-mode
images. Two-dimensional echocardiography was used to
image the cardiac structures in both the substernal long axis
and short axis views. These echocardiographic views were
then used to position the M-mode echocardiographic line. In
the long axis, the probe was oriented toward the base of the
heart projecting toward the apex (x-axis) with depth along the
y-axis, thus allowing pulse wave Doppler evaluation of
valvular blood ﬂow velocities. In short axis procedures, the
probe was oriented toward the left ventricle and across the
heart for evaluation of wall structure, which was used in the
calculation of ejection fraction and fractional shortening
during systole. M-mode displays were analyzed by a digital
echocardiographic analysis system. Six measurements were
selected for each assessment of cardiac structure and function.
Structural parameters included: diastolic (IVSd) and systolic
(IVSs) left ventricular septal thickness, diastolic (LVIDd) and
systolic (LVIDs) left ventricular internal dimension, diastolic
(LVPWd) and systolic (LVPWs) left ventricular posterior wall
thickness, and right ventricular diastolic internal dimension
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Table 2. Echocardiographic evaluation of cardiac structural parameters in the experimental groups of gerbils.
Group

N

IVSd (cm)

IVSs (cm)

SC
IO
IOAi
IOAo
IODF

16
15
9
10
7

0.09 ± 0.01
0.13 ± 0.01*
0.09 ± 0.01+
0.09 ± 0.02+
0.10 ± 0.01+

0.15 ± 0.01
0.19 ± 0.01*
0.14 ± 0.01+
0.15 ± 0.02+
0.15 ± 0.01+

LVIDd (cm)

LVIDs (cm)

0.43 ± 0.01
0.27 ± 0.01
0.53 ± 0.02* 0.35 ± 0.01*
0.44 ± 0.01+ 0.30 ± 0.01*+
0.48 ± 0.02+ 0.31 ± 0.02*+
0.43 ± 0.02+ 0.27 ± 0.01+

LVPWd (cm) LVPWs (cm)
0.11 ± 0.01
0.17 ± 0.01*
0.11 ± 0.01+
0.10 ± 0.01+
0.12 ± 0.01+

0.14 ± 0.01
0.19 ± 0.01*
0.15 ± 0.01+
0.16 ± 0.02+
0.15 ± 0.01+

RV (cm)
0.14 ±0.01
0.20 ± 0.01*
0.12 ± 0.01+
0.12 ± 0.02+
0.14 ± 0.01+

An asterisk (*) or cross (+) indicates signiﬁcant diﬀerence (p < 0.05) from saline control (SC) and iron-overload (IO) groups,
respectively. See Materials and Methods for abbreviations.

Table 3. Echocardiographic evaluation of cardiac functional parameters in the experimental groups of gerbils.
Group

EF (%)

SC
IO
IOAi
IOAo
IODF

77.5 ± 1.5
60.6 ± 1.8*
72.5 ± 1.7*+
76.4 ± 1.7+
67.1 ± 1.1*,+

FS %)

AV Max (cm/sec) PV Max (cm/sec) MV Max (cm/sec)

40.4 ± 1.5
47.2 ± 2.5
27.9 ± 1.3*
49.8 ±2.4
35.0 ± 2.0*+ 70.4 ± 4.0*+
39.3 ± 1.3+ 58.6 ± 3.3*,+
34.1 ± 2.4*,+ 53.4 ± 3.9

48.9 ± 3.2
52.9 ± 4.2
66.2 ± 4.4*+
58.1 ± 4.0*
47.6 ± 3.2

41.0 ± 3.9
38.0 ± 3.7
50.7 ± 2.9*+
44.3 ± 3.4
39.8 ± 3.2

TV Max (cm/sec)
40.3 ± 2.6
38.1 ± 3.1
51.0 ± 4.0*+
37.0 ± 1.8
37.6 ± 2.3

An asterisk (*) or cross (+) indicates signiﬁcant diﬀerence (p < 0.05) from saline control (SC) and iron-overload (IO) groups,
respectively. See Materials and Methods for abbreviations.
(RV). Functional measurements included: ejection fraction
(EF), left ventricular fractional shortening during systole
(FS), maximal aortic (AVmax), pulmonary (PVmax), mitral
(MVmax), and tricuspid (TVmax) valvular blood ﬂow
velocities. In addition to direct measurements of cardiac
mass, echocardiographic measurements were utilized to
estimate left ventricular mass (LVM) as previously described
[30]: LVM = 1.04 (LVIDd + IVSd + PWd)3 - (LVId)3.
The wavelength of an ultrasonic pulse is calculated using
the formula λ = V/F = velocity of pulse in tissue/frequency of
pulse. Pulse velocity in tissue is approximately 1,500 m/sec
[28-30], so λ = 0.125 mm with a 12 MHz transducer. ECHO
resolution is the smallest distance between 2 points at which
the points can be distinguished as separate [28]. Resolution =
wavelength times pulse length, and the pulse length was 1
sec. Therefore, we were able to accurately measure cardiac
wall thicknesses of approximately 0.125 mm or greater.
Sensitivity is the ability of a system to image small targets
located at speciﬁc depths in an attenuative medium [28]. It is
determined by the transducer transmitting eﬃciency times
the transducer receiving eﬃciency of the reﬂected pulse
(echo). System eﬃciency is inﬂuenced by transducer beam
geometry, frequency spectrum, and energy conversion
eﬃciency. The typical transducer used in ECHOs of adult
patients is about 2.25-MHz and has an eﬃciency of about
4.4% [28]. 3.5-MHz transducers are typically used in younger
children and 5-MHz transducers in infants and neonates. In
the gerbils, a 12-MHz transducer was used and the beam
traveled a much shorter distance to detect gerbil hearts,
compared to human hearts, so that the system eﬃciency
should be considerably greater.

Liver and cardiac iron content. After completion of the
echocardiographs (12-13 wk), the gerbils were euthanized by
exsanguination via cardiac puncture or by carbon dioxide
inhalation. Hearts and livers were removed by dissection,
weighed to the nearest mg, frozen in liquid nitrogen, and
stored at -70°C until analysis. Whole hearts and liver samples
were digested in concentrated nitric and perchloric acids
(70:30, v/v). Iron concentration was determined in tissue
digestates by inductively coupled plasma-atomic emission
spectrometry (ICP-AES) [31].
Histological techniques. Animals from each group were killed
after completion of treatment and ECHO procedures. Six
animals were histologically evaluated from each group. Whole
hearts (breadloaf sectioned) and representative sections of
liver, spleen, pancreas, and testes were ﬁ xed in 10% buﬀered
formalin solution and processed into paraﬃn blocks by
routine procedures. Representative 3-5 μm slices were cut
with a cryostat and sections were mounted on glass slides for
staining with hematoxylin and eosin (H & E), Perls iron
stain, or Mallory trichrome stain. Bone marrow samples were
obtained from cross-section blocks of gerbil spinal column
and from femurs and were ﬁ xed in B-5 solution after light
decalciﬁcation, processed, sections cut and mounted on glass
slides, and stained with H & E or Perls iron stain. Slides were
evaluated by light microscopy.
Studies in vitro. Five ml of acetaminophen (10 -3 M, clear
solution) was added to 5 ml of Fe(II)SO4•7H2O (10 -3 M,
clear solution) or Fe(III)Cl3•6H2O (10 -3 M, light yellow
solution) in glass scintillation vials that were capped, shaken
periodically, and observed at 23°C for up to 48 hr.
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Statistics. Data were expressed as means ± SD. Statistical
analyses were performed using Sigma Stat statistical software
(Jandel Corporation, San Rafael, CA). Diﬀerences among
groups were assessed by 2-way ANOVA, followed by Tukey
test. Values of p ≤ 0.05 were deemed statistically signiﬁcant.

Results
Cardiac structure and function. Iron overloading
resulted in signiﬁcant increases in left ventricular
septal (IVSd, IVSs) and posterior wall (LVPWd,
LVPWs) thicknesses as well as left (LVIDd, LVIDs)
and right ventricular (RV) internal dimensions
(Table 2). Treatments with either acetaminophen
or deferoxamine by ip injection were equally
eﬀective in preventing iron overloading-induced
changes in cardiac structure. Oral administration
of acetaminophen also prevented iron-induced
changes; the decreases in left ventricular dimensions
(LVIDd, LVIDs) were statistically diﬀerent from
the values obtained in IO animals.
Iron-overloading resulted in signiﬁcant
decreases in the ejection fraction (-22%) and left
ventricular fractional shortening during systole (31%), with little or no change in valvular blood
ﬂow velocities (Table 3). Both oral administration
and ip injection of acetaminophen prevented these
losses in function. Deferoxamine ip signiﬁcantly
prevented or reversed iron-induced decreases in
ejection fraction and left ventricular fractional
shortening (FS) during systole. The ip injections of
acetaminophen caused a signiﬁcant increase in
maximal aortic (AVmax), pulmonary (PVmax),
and tricuspid (TVmax) valvular blood ﬂow velocity,
suggesting a positive inotropic eﬀect of the drug.
Tissue iron evaluation. Iron overloading resulted
in 232-fold increase in liver and 16-fold increase in
cardiac iron content (Fig. 1). Treatments with either
acetaminophen (ip, oral) or deferoxamine (ip) were
roughly equal in partially reducing the cardiac iron
burden in iron-overloaded animals. Average posttreatment cardiac iron concentrations were: SC,
15.11 ± 11.77 ug; IO, 243.36 ± 51.08 ug; IOAi,
130.38 ± 29.58 ug; IOAo, 133.76 ± 27.95 ug; IODF,
110.50 ± 7.47 ug (p values IOAi vs IOAo or DF
>0.05; IOAo vs DF >0.05). As shown in Fig. 1,
acetaminophen (ip, oral) appeared less eﬀective
than deferoxamine (ip) in reducing hepatic

Fig. 1. Hepatic and cardiac iron content of gerbils in the
experimental groups. The iron content of liver (A) and heart
(B) of saline controls (SC, n = 10), iron-overloaded (IO, n =
10), acetaminophen-injected (IOAi, n = 9), acetaminophen
administered by oral gavage (IOAo, n = 10), and deferoxamineinjected gerbils (IODF, n = 7).
An * or + indicates a signiﬁcant diﬀerence (p <0.05) from the
controls or iron-overloaded gerbils, respectively.

concentrations of excess iron. Average posttreatment hepatic iron concentrations were: SC,
0.201 ± 0.016 mg; IO, 46.623 ± 1.457 mg; IOAi,
33.139 ± 6.780 mg; IOAo, 33.516 ± 6.812 mg;
IODF, 19.567 ± 1.636 mg (p values IOAi vs IOAo
>0.05; IOAi or IOAo vs DF <0.05).
Iron accumulation was noted in most gerbil
tissues with the least in the central nervous system.
In iron-overloaded gerbils, hemosiderin iron
deposition was seen in gerbil liver (Fig. 3A),
pancreas (Fig. 3B), spleen (Fig. 3D), myocardial
cells and interstitial spaces (Fig. 2A,C), aorta (Fig.
2D,E), kidney (Fig. 3C), pituitary, thyroid, bone
marrow, and testes. The cardiovascular system
demonstrated iron accumulation in myocardial
cells, and interstitial spaces (Fig. 2A,C), while the
aortas accumulated iron in all vascular layers, most
marked in tunica adventitias and tunica intimas
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(Fig. 2D,E). Sections of left ventricle from ironoverloaded gerbils showed areas of iron-induced
destruction and necrosis of cardiac muscle (Fig.
2B). Liver sections stained with iron stain (Prussian
blue) demonstrated accumulation of hemosiderin
iron granules in cytoplasm of hepatocytes, most
marked in periportal areas (Fig. 3A) and often
perinuclear in location (arrow). Pancreases were
intensely pigmented with hemosiderin accumulation
in acinar and islet cells (Fig. 3B). Renal sections
revealed tubular and glomerular accumulations of
hemosiderin granules (Fig. 3C). Spleens showed
marked hemosiderin accumulation in both red and
white pulp (Fig. 3D). Hemosiderin granules accumulated in sections of bone marrow (not shown).
Testes accumulated iron chieﬂy in interstitial spaces
among seminiferous tubules, but little within
tubules (not shown). Hemosiderin iron accumulated
in the adrenal and thyroid glands (not shown).
Both acetaminophen (ip or oral) and deferoxamine
(ip) produced substantial iron reductions in the
tissues (liver, heart, aorta, spleen, pancreas, bone
marrow, testis, adrenal, and thyroid), with the least
reduction in liver and spleen, as judged from
histological evaluations. The body weights of ironoverloaded gerbils were similar to saline controls,
indicating that the injections of iron dextran did
not result in debilitation and weight loss (Table 4).
By comparison, liver and cardiac weights were
increased 40% and 43%, respectively, in the IO
group. Consistent with echocardiographic evidence
of hypertrophy and increase in heart weight,
calculation of left ventricular mass indicated an
approximate increase of 130% in the left ventricular
mass of iron overloaded animals compared to
controls (Table 5). Acetaminophen (ip, oral) and

Table 5. Left ventricular mass calculated from echocardiographic analysis of gerbils in the control (SC), iron
overloaded (IO), acetaminophen treatment by ip injection
(IOAi), acetaminophen treatment by gavage (IOAo), and
deferoxamine treatment by ip injection (IODF) groups.
Group

N

LVM (g)

SC
IO
IOAi
IOAo
IODF

16
15
9
10
7

0.177 ± 0.005
0.408 ± 0.13*
0.189 ± .007+
0.205 ± .006*+
0.222 ± .017*+

An asterisk (*) or cross (+) indicates a signiﬁcant diﬀerence (p
<0.05) from the groups of control (SC) or iron-overloaded
(IO) gerbils, respectively.

deferoxamine (ip) appeared equally eﬀective in
reducing the increases in liver and cardiac weights
(Tables 4 and 5).
Mortality and arrhythmias. During the total
period of observation, of 16 saline control (SC)
gerbils, 0 developed cardiac arrhythmias (ECHO
studies) and there were 0 deaths. Of 16 ironoverloaded (IO) gerbils, 9 developed signiﬁcant
cardiac arrhythmias, chieﬂy premature ventricular
contractions (PVCs), and 3 of the 9 gerbils died
after completion of ECHOs and prior to the end of
the experiments. The 16 iron-overloaded gerbils
treated by acetaminophen ip (IOAi) showed 0
cardiac arrhythmias and 1 death. The 16 ironoverloaded gerbils treated orally with acetaminophen
(IOAo) demonstrated 1 animal with cardiac
arrhythmia (PVCs) and 0 deaths. The 16 ironoverloaded gerbils treated with deferoxamine ip
showed 3 animals with cardiac arrhythmias (PVCs),
which died prior to the end of the experiment.

Table 4. Body, liver, and heart weights of gerbils in the experimental groups.
Group

Body wt (g)

Liver per body wt (%)

Heart per body wt (%)

SC
IO
IOAi
IOAo
IODF

83.7 ± 2.2
80.5 ± 2.6
85.3 ± 2.4
84.2 ± 2.3
92.6 ± 5.6

4.10 ± 0.06
5.78 ± 0.32*
4.93 ± 0.13*+
5.14 ± 0.20*+
4.94 ± 0.11*+

0.31 ± 0.01
0.46 ± 0.01*
0.40 ± 0.01*+
0.40 ± 0.01*+
0.37 ± 0.01*+

An asterisk (*) or cross (+) indicates a signiﬁcant diﬀerence (p < 0.05) from saline control (SC) and iron overload (IO) groups,
respectively. See Materials and Methods for abbreviations.
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Fig. 2. Cardiac (A-C) and aortic (D and E) iron deposits in iron-overloaded gerbils (group IO): 2A depicts iron accumulations
(blue granules) in cardiac interstitial cells and cardiomyocytes (Perls iron stain, 100X); 2B depicts iron-induced damage and
necrosis of cardiac muscle (H&E, 100X); 2C shows iron accumulations (blue granules) in cardiac interstitial cells and
cardiomyocytes (Perls iron stain, 100X); 2D demonstrates iron deposits in all layers of iron-overloaded aortic wall, but especially
concentrated in the adventitial area (Perls iron stain, 40X); 2E is a higher power view of 2D (Perls iron stain, 400X).

In vitro study. Acetaminophen reacted in vitro
with Fe(II)SO4•7H2O (ferrous) (10 -3 M, clear
solution) to produce a brown precipitate and with
Fe(III)Cl3•6H2O (ferric) (10-3 M, light yellow
solution ) to yield a rusty-appearing solution, which
gradually turned dark brown and formed a brownblack precipitate. These observations suggest that
acetaminophen can bind to iron in vitro.
Discussion
The results of this study suggest that acetaminophen
is equally eﬀective as deferoxamine in cardiac iron
removal and the prevention or reversal of cardiac
functional and structural abnormalities in the ironoverloaded gerbil model. ECHO and radionuclide
ventriculography are the most useful noninvasive
diagnostic techniques to detect iron-overloadinduced cardiomyopathy [32]. Our ECHO studies
revealed easily discernable diﬀerences in cardiac

structure and function between the saline control
and iron-overloaded groups and between the ironoverloaded group and the iron-overloaded treated
groups.
Iron localization in human hearts. Normally, there
is no stainable iron within the myocardium [33].
In cases of iron-overload, iron-saturated transferrin
attaches to transferrin receptors on cardiomyocytes
and iron is released into the cell to be stored as
hemosiderin-iron [32]. In iron-overloaded human
patients, excess iron accumulates in cardiomyocytes,
cardiac macrophages, in cells of the bundle of His
and Purkinje system, and in interstitial spaces of
the heart [32]. In cases of hemochromatosis or
hemosiderosis, iron deposits tend to be more
extensive in the epicardial third of the ventricle,
followed by the subendocardium and papillary
muscle, and least in the middle third of the
ventricular wall. Hematoxylin and eosin as well as
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Fig. 3. Liver (A), pancreatic (B), kidney (C), and splenic (D) iron deposits in iron-overloaded gerbils (group IO): 3A reveals iron
deposits in hepatocytes and Kupﬀer cells. Perinuclear iron distribution occurs in hepatocytes (arrow) (Perls iron stain, 40X); 3B
shows iron distribution in pancreas, emphasizing iron deposits in pancreatic cells, including islet and beta cells (Perls iron stain,
400X); 3C illustrates iron in kidney (blue granules) including glomerular and tubular iron deposits and tubular damage (Perls
iron stain, 100X); 3D shows iron distribution (blue granules) in splenic red and white pulp (Perls iron stain, 100X).

Prussian blue staining show hypertrophic myocytes
with hemosiderin iron in perinuclear locations in
cells, but with increased iron concentrations
eventually occupying most of the cells and
occasionally totally replacing myocytes [33]. Iron
accumulations in the cardiac conduction system,
coronary arteries, and valves are usually limited,
but involvement of the conduction system is
associated with cardiac arrhythmias. Iron accumu-

lation in the bundle of His and Purkinje system
may impair signal conduction from the atrial pacemaker to the ventricles and this may result in
arrhythmias and sudden death [32]. Cardiac ﬁbrosis
may be present and result in restrictive cardiac
hemodynamics [33]. There is signiﬁcant correlation
between serum ferritin concentrations and the
endomyocardial biopsy grade. Patients with high
ferritin levels and poor compliance to treatment
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with chelating agents are at high risk of cardiac
hemochromatosis and its complications [33].
Iron localization in gerbil hearts and aortas. Iron
distribution in the gerbil hearts was almost identical
to that reported in human hearts. Marked iron
accumulations were seen in the ventricles, less in
atria, and little in ﬁbers of the conduction system,
valves, or coronary arteries. Appreciable quantities
of iron accumulated in gerbil aortas, especially in
the adventitial region. Iron accumulations were
evident in cardiomyocytes, cardiac macrophages,
and interstitial spaces. Inﬁltrating ﬁbrosis in gerbil
heart ventricles was similar to that which sometimes
occurs in hearts of iron-overloaded patients.
Hemosiderin iron is innocuous, but it is in
equilibrium with a small pool of loosely bound
(“free”) iron in cardiomyocytes. Loosely bound
iron is capable of catalyzing the formation of ROS
(reactive oxygen species) through the Fenton
reaction. The ROS can cause oxidant-mediated
injury to cells. Cardiac cells are particularly sensitive
to oxidant-induced damage since they contain a
high concentration of mitochondria and maintain
a high degree of metabolic function, which includes
performing complex operations such as contraction
and transmission of electrical impulses [32]. By
binding iron, deferoxamine and acetaminophen
may reduce or prevent the generation of ROS via
the Fenton reaction, thus protecting against cellular
damage and restoring normal cellular activity.
Pathogen-free Mongolian gerbils were used in
this study to avoid the increased morbidity and
mortality and advanced hepatocellular necrosis
observed in gerbil strains (eg, Psammomys obesus)
with coincidental laboratory infections [14].
Acetaminophen was as eﬀective as deferoxamine in
reducing cardiac excess iron content and preventing
echocardiographic evidence of cardiotoxicity in
iron-overloaded gerbils. Acetaminophen and
deferoxamine treatments both reduced hepatic
excess iron content, although acetaminophen was
less eﬀective than deferoxamine. This may be due
to tight binding of iron to the high concentrations
of ferritin and similar molecules in the liver.
The gerbil iron-overload model was ﬁrst
described by Carthew et al [34] and provides an
excellent experimental model for the study of iron-

overloading of the heart and liver. Iron overloading
in the gerbil model closely simulates the features
observed in transfusion iron-overloaded patients
[34]. Weekly injections of iron dextran in gerbils
result in accumulation of ferritin in perisinusoidal
cells, Kupﬀer cells, and hepatocytes with subsequent
scarring hepatic ﬁbrosis [35] and suppression of
mitochondrial respiratory enzyme activities [39].
Others have shown the development of cardiomyopathy in the iron-overloaded gerbil [14,37-41].
Subepicardial and subendothelial areas and the
intraventricular septum in gerbil hearts were
primarily aﬀected, as occurs with severe iron
overload in humans. Similarly, intracellular iron in
individual myocytes showed a characteristic
perinuclear pattern in gerbils, as seen in human
hemochromatosis. Within 12 wk from the start of
iron administration, iron-overload in the gerbil
resulted in signiﬁcant increase of cardiac iron
content with progressive development of hypertrophy, electrocardiographic abnormalities, and
reduced function. The similarities of iron accumulation, distribution, and associated pathology in
gerbil and human hearts and their similar responses
to iron-removing therapy emphasize the value of
the Mongolian gerbil iron-overload model in
studying iron-induced cardiovascular pathology
and therapeutic interventions.
Our study showed iron-induced changes in
cardiac structure and function in the gerbil model
based on echocardiographic ﬁndings. Consistent
with previous reports, the present results indicate
cardiac hypertrophy with possible ventricular
distension (Table 2) and signiﬁcant reduction in
function (Table 3). Similar to previous studies
[14,36,39,41], we found that chelation therapy with
deferoxamine prevents functional abnormalities in
the gerbil model. Furthermore, we demonstrated
that oral or ip administration of acetaminophen
partially or totally prevents the changes in structure
and cardiac function. Acetaminophen and deferoxamine were equally eﬀective in reducing excess
cardiac iron. Acetaminophen and deferoxamine
both reduced the accumulation of iron in livers and
hearts of iron-overloaded gerbils (Fig. 1). Acetaminophen provided signiﬁcant cardio-protection
when given either by ip injection or oral gavage.
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Possible mechanisms of action. The mechanism by
which acetaminophen provides cardioprotection
against iron-overload is uncertain. At high doses
and prolonged use, acetaminophen is a hepatotoxin
due to its ability to form free radicals and deplete
glutathione stores [42,43]. Conversely, acetaminophen can also be considered an antioxidant due to
its ability to protect membranes from lipid oxidation
by scavenging peroxyl radicals and peroxynitrite
[44]. In addition to its actions against hydroxyl
radicals and hydrogen peroxide, acetaminophen
has also been shown to be eﬃcacious against
peroxynitrate [45], myeloperoxidase [46], cyclooxygenase [47], and other peroxides [48]. Acetaminophen provides cardioprotection to the postischemic,
reperfused guinea pig myocardium [49,50]. Given
before or during ischemia-reperfusion periods,
acetaminophen treatment produced positive
inotrophic eﬀects, lower coronary perfusion
pressure, lower coronary vascular resistance,
retention or recovery of a greater percentage of left
ventricular function, preservation of myoﬁbrillar
ultrastructure, attenuation of bursts of hydroxyl
radicals during reperfusion, reduced release of
creatine kinase during ischemia-reperfusion,
reduced production of peroxynitrate, attenuation
of damaging eﬀects of peroxynitrate and hydrogen
peroxide via protein oxidation, and reduced
perturbations of myocardial electrical stability.
In conclusion, increases in ROS (reactive
oxygen species) may represent the underlying
mechanism of iron-induced cardiac and tissue
damage. Therefore, the reduction of excess cardiac
and tissue iron accumulations should combat the
iron-associated organ and tissue damage. Previous
observations suggest that acetaminophen provides
signiﬁcant functional and structural cardiac
protection, probably by its antioxidant properties
[26]. Therefore, the antioxidant characteristics of
acetaminophen might provide cardioprotection
and prevent tissue or organ damage in a number of
conditions such as increased iron concentrations,
which induce the release of free radicals and other
oxidants [1]. In the present study, it seems likely
that acetaminophen may have provided cardioprotection by dual mechanisms: (a) its antioxidant
eﬀects and (b) the removal of excess cardiac iron.

Speculative mechanisms of iron-binding by
acetaminophen. Possible mechanisms of iron
removal include (a) direct chelation or complexing
of acetaminophen with iron (ferrous and ferric?)
and (b) reaction of ferric iron with [NAPQI•] (Nacetyl-p-benzoquinoneimine), the hepatic toxic
metabolite of acetaminophen, to form iron-NAPQI
complexes. NAPQI normally reacts with sulfhydryl
groups of glutathione to form a nontoxic complex.
However, at very high levels, excess NAPQI, not
detoxiﬁed by glutathione, may react with sulfhydryl
groups of hepatic proteins to form covalent bonds,
which lead to cellular necrosis and death [51]. If
iron is capable of reacting with NAPQI to form a
nontoxic complex, protection may be provided.
Future areas for study. That acetaminophen is able
to mobilize excess iron from the heart and other
organs is a novel observation. Acetaminophen has
been used as an analgesic-antipyretic agent for
many decades, so that much is known about its
therapeutic and toxic characteristics. The demonstration that acetaminophen is orally eﬀective as an
iron removing agent is potentially important, since
there is a shortage of approved oral agents that are
therapeutically eﬀective in iron removal. However,
knowledge in key areas regarding acetaminophen
removal of iron is lacking. These areas must be
investigated to ensure the clinical safety and
therapeutic eﬃcacy of acetaminophen in its ironremoving role before human clinical trials can be
recommended. The areas include: (a) mechanisms
(chelation or complexing) of acetaminophen
binding to iron and mobilization of excess tissue
iron, (b) routes of elimination (urinary or biliary)
of acetaminophen-iron complexes, and (c) studies
to determine why acetaminophen is less eﬀective in
mobilizing iron from some organs (liver, spleen)
than others (heart, kidney) and whether acetaminophen binding to hepatic iron is associated with
redistribution of soluble iron chelates.
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